Trial Profile
A Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent Resolute Onyx 2.0 mm Clinical Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jul 2019
Price :
$35
*
At a glance
- Drugs Zotarolimus (Primary)
- Indications Coronary artery disease; Ischaemic heart disorders
- Focus Registrational; Therapeutic Use
- Sponsors Medtronic
- 22 Mar 2019 Status changed from active, no longer recruiting to completed.
- 28 Apr 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2017.
- 24 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.